Pomalidomide S.K. in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Pomalidomide S.K. in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
**Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
*** Disclaimer
The information provided herein is not intended as medical advice and must not be relied upon for diagnosis, treatment, or the provision of medical care. It does not replace the official prescribing/patient leaflet or consultation with a qualified healthcare professional. Before any use, always review the official physician/patient leaflet and consult a licensed physician. The company assumes no responsibility or liability for any reliance placed on the information presented on this page.
